

Anti-CD20 Antibody (Ocrelizumab)

Introduction

Ocrelizumab (Ocrevus) is a humanized anti-CD20 monoclonal antibody that induces B cell depletion and inhibits multiple sclerosis lesions in mice via antibody-dependent cellular cytotoxicity (ADCC).

Product parameters

Alternative Names	PRO70769, RG1594
Target Accession	P11836
Target	CD20
CAS number	637334-45-3
Molecular Weight	145.82 kDa
Host	CHO
Reactivity	Human, Cynomolgus
Conjugation	Unconjugated
Form	Liquid
Concentration	See label
Buffer System	100 mM Pro 20 mM Arg pH 5.0. No preservative!
Clonality	Monoclonal
Purification	Protein A
Isotype	IgG1
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	Human CD20 CHO-K1 cells were stained with Anti-CD20 Antibody (Ocrelizumab) and negative control protein respectively, washed and then followed by PE and analyzed with FACS, EC50=0.48 ug/mL.
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 µM filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

Note

1. This product is for scientific research use only.



APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

